LinqAlpha
Builds AI agents for institutional investors to surface market-moving signals in public markets
$22MSeries A
Role not disclosedSS
Samsung Securities
Activity from announced rounds
Activity in this selectionFintech
Samsung Securities is the securities company identified by LinqAlpha and as a new investor by ImpriMed.
Recorded funding activity
LinqAlpha develops research agents for institutional investing. ImpriMed combines live-cell drug testing with clinical data. The corporate investor remains distinct from Samsung Electronics and Samsung Ventures.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $22M 1 disclosed · full round size, not this investor’s share